Past Clinical Trials in Houston, TX

A Double-Blind, Placebo-Controlled Study of Ceftobripole Versus Vancomycin and Ceftazidime in Patients with Skin Infections (Johnson and Johnson)

SCRAPE Study (Glaxo SmithKline)

A Randomized, Evaluator-Blinded, Phase 2 study to Compare the Safety and Efficacy of PTK 0796 with Linezolid in the Treatment of adults with Complicated Skin and Skin structure. Protocol Number: PTK0796-CSS1-0702 (Paratek)

A Randomized, Controlled, Double-Blind, Double-Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared with Linezolid (Zyvox) for The Treatment of Complicated Skin and Skin Structure Infection. (Furiex)

Nuvicid (Oritavancin) at Single or Infrequent doses for the Treatment of Complicated Skin and Skin Structure Infections (TARGANTA; TAR-ORI-SD0001)

A Randomized, Double-blind, Multicenter Study of RX-3341 compared with Tigecycline for the Treatment of Complicated Skin and Skin Infection. (RIB-X RX334-201)

A Phase 3, Multicenter, Double-blind, Comparative Study to evaluate the safety and efficacy of Ceftatroline versus Vancomycin in Adult Subjects with Complicated Skin and Skin Structure Infection. (P903-07)

A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and skin Structure Infections. (Trius)

A Phase 2 Exploratory study of Objective Endpoints in Subjects with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Vancomycin or Linezolid. (RX-3341-202)

A Phase 3 Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin structure Infections.

A Multicenter, Double-Blind, Randomized study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of patients with Acute Bacterial Skin and Skin Infection Structure Infection (ABSSSI). (SOLOII)

A Randomized, Double-blind, Multicenter Placebo-controlled, Phase III Superiority Study to assess the safety and Efficacy of Topical Retapamulin Ointment, 1% versus Placebo Ointment applied twice daily for 5 days in the treatment of Adult and Pediatric Subjects with Secondary-Infected Traumatic Lesions (GSK TOC110977)

A Phase 3, Randomized, Double-Blind, Double-Dummy study to compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

A Randomized, Prospective, Double-Blind, Vehicle-controlled, Dose-ranging, Multi-Center Study to Assess the Safety and Clinical Effect of Nexagon® (NEXAGON) in the Treatment of Subjects with a Diabetic Foot Ulcer.

A Randomized, Double-Blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects with Diabetes Mellitus. (Derma Sciences)

Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03 DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers (“DFU”) DSC127-2012-05. (Derma Sciences)

A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-Healing Foot Ulcers in Subjects with Diabetes Mellitus DSC127-2012-02. (Derma Sciences)

A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to adults with Moderate or Severe Diabetic Foot Infections (MRXC-302)

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (EN3835-222)

A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis (EN3835-306)

EN3835-108 PFA: A Phase 1, Single Blind, Randomized, Placebo Controlled Dose Escalation Study to Assess the Safety, Effectiveness and Tolerability of a Single Treatment of EN3835 VS Placebo for Recalcitrant Plantar Fasciitis (PFA)

A Phase 3, Double Blind, Randomized, Placebo-Controlled study to assess the efficacy, safety, and tolerability of EN3835 vs placebo in the treatment of plantar fibromatosis (PFI) (Also known as ledderhose disease)

A Phase 3, observational, multi-center, extension study to evaluate the long-term safety, effectiveness, and persistence of effect on EN3835 in the treatment of plantar fibromatosis (PFI) (Otherwise known as ledderhose disease) (Long-Stride)

A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXXX in Patients with Diabetic Neuropathy (Dong A Pharmaceutical)

“The Balance Study – Treatment of Hyponatremia based on Lixivaptan in NYHA class 111/1V Cardiac patient evaluation.” October 15, 2008 to date (Cardiokine) 

ARISTOTELE study, epixiban in atrial fibrillation. May 1, 2008 (Bristol Myers) 

“Reduction of Atherothrombosis for Continued Health”. REACH REGISTRY 2004 (Sanofi-Synthelabo and Bristol-Myers Squibb) 

“Valsartan – Managing Blood Pressure Aggressively and Evaluation Reduction in CRP”. VAL-MARC (2004) 

“The Efficacy and Safety of Omapatrilat added to Hydrochlorothiazide for the Treatment of Hypertension in Subjects Non-Responsive to Hydrochlorothiazide Alone”. CV137-137-2002 (Bristol-Myers Squibb) 

“A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS). SYNERGY 2002 (Aventis) 

“A Randomized, Double-Blind, Placebo-Controlled Study of Two Intravenous Dosing Regimens of h5G1.1-scFV in Patients with Acute Myocardial Infarction Undergoing Thrombolytic Reperfusion Therapy.” COMPY 2001 (Procter & Gamble) 

“A Single-Arm, Open Label study of Cerivastatin (Baycol) in community-based patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease”. CRISP 2001 (Bayer Corp.) 

“TEST”. Eprosartan Mesyolate Efficacy and Safety Trial, 200 (Unimed) 

“An Open-Label Evaluation of the Effectiveness of Verelan PM (verapamil HCI) in the Control of Morning Blood Pressure Following Bedtime Dosing in Patients with Essential Hypertension. CHRONO.” 1999 (Schwarz Pharma) 

“A Multinational, Multicenter, Double-Blind, Randomized, Active-Controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction. VALIANT.” 1999 (Novartis) 

“A Phase III Multicenter, International, Randomized, Double-Blind, Aspirin-Controlled Trial to evaluate the efficacy and safety of Xubix (Sibrafiban; Ro 48-3657), an oral platelet glycoprotein IIb/IIIa receptor antagonist, as therapy for the long term prevention of secondary vascular events in patients after an Acute Coronary Syndrome. Second Symphony.” 1999 (Roche) 

“A Randomized, Double-Blind, Placebo-Controlled Study of Lamifiban (Ro 44-9883) in patients with unstable angina/non-Q wave myocardial infarction. PARAGON B.” (Roche) 

“An Evaluation of the Safety and Effectiveness of Avapro-Irbesartan for the Treatment of Hypertension: A Post-Marketing Surveillance Study.” 1998 (Bristol-Myers Squibb) 

“Open-Label Long-Term Study in patients with Chronic Heart Failure Who Participated in Controlled Clinical Studies with Bosentan NC 15464B.” (Roche) 

“MERIT-HF, A Double-Blind, Placebo-Controlled Survival Study with Metoprolol CR/XL in Patients with Decreased Ejection Fraction and Symptoms of Heart Failure.” (Astra) 

“Double-Blind Randomized, Placebo-Controlled Study to Assess the Effects of RO 47-0203 (Bosentan) on the Clinical Status of Patients with Advanced Chronic Heart Failure and the Pharmacokinetics of RO 47 0203 (Bosentan).” (Roche) 

“MACH-1, Double Blind, Placebo-Controlled Study of RO-596. (Mortality in Chronic CHF (Mibefridil)).” November 1994 to 1998 (Roche) 

“A Double Blind, Placebo-Controlled Study of Cilazapril versus Captopril in Patients with Chronic Congestive Heart Failure.” 1984-1986 (Roche) 

“A Placebo Controlled Study of Betaxolol in Patients with Stable Angina of effort.” A Multicenter Study: 1985-1986